Published in J Clin Invest on November 01, 1996
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96
The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest (2002) 3.21
Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest (2000) 2.27
Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induces epithelial prostaglandin h synthase-2 expression and prostaglandin E2 and F2alpha production. J Clin Invest (1997) 1.68
Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol (1999) 1.65
Three-dimensional tissue assemblies: novel models for the study of Salmonella enterica serovar Typhimurium pathogenesis. Infect Immun (2001) 1.58
Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med (1998) 1.58
Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol (1999) 1.54
Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions. Nat Rev Microbiol (2010) 1.46
Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J Immunol (2010) 1.31
Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut (2001) 1.29
The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol (2000) 1.27
Cyclooxygenase-2 contributes to dysmotility and enhanced excitability of myenteric AH neurones in the inflamed guinea pig distal colon. J Physiol (2004) 1.20
The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol (2012) 1.20
Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br J Pharmacol (2005) 1.17
Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology (1998) 1.16
Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis (2010) 1.15
Cox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis. Carcinogenesis (2010) 1.14
Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci U S A (2002) 1.13
Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut (2008) 1.12
Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol (2000) 1.09
Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells. J Immunol (2006) 1.08
Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol (1999) 1.07
The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br J Pharmacol (2004) 1.07
Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut (2003) 1.06
Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol (2009) 1.05
Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. Br J Pharmacol (2000) 1.03
Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis. J Immunol (2011) 1.03
NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol (2012) 1.03
Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol (2001) 1.03
Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Dig Dis Sci (2001) 1.02
A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci U S A (2010) 1.01
Transactivation of EGFR by LPS induces COX-2 expression in enterocytes. PLoS One (2012) 0.99
Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut (2001) 0.98
Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut (2000) 0.96
COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors. Gut (2000) 0.94
Non-steroidal anti-inflammatory drugs and perforated diverticular disease: a case-control study. Ann R Coll Surg Engl (2002) 0.92
Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci (2006) 0.90
Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice. Dig Dis Sci (2012) 0.89
IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. Proc Natl Acad Sci U S A (2000) 0.89
Effect of cyclooxygenase genotype and dietary fish oil on colonic eicosanoids in mice. J Nutr Biochem (2011) 0.87
Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. Am J Pathol (2005) 0.87
TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2011) 0.87
Selective COX-2 inhibition is associated with decreased mucosal damage induced by acid and pepsin in rabbit esophagitis. Inflammation (2003) 0.85
The role of PGE2 in intestinal inflammation and tumorigenesis. Prostaglandins Other Lipid Mediat (2014) 0.84
Atherogenic diet causes lethal ileo-ceco-colitis in cyclooxygenase-2 deficient mice. Prostaglandins Other Lipid Mediat (2007) 0.83
Nitric oxide-releasing aspirin but not conventional aspirin improves healing of experimental colitis. World J Gastroenterol (2011) 0.83
Targeting interleukin 18 with interleukin 18 binding protein. Ann Rheum Dis (2000) 0.83
Cyclooxygenase inhibition attenuates cholecystokinin-induced gastroprotection. Dig Dis Sci (1998) 0.82
Structural biology of the IL-1 superfamily: key cytokines in the regulation of immune and inflammatory responses. Protein Sci (2014) 0.81
Protective role of hydrogen-rich water on aspirin-induced gastric mucosal damage in rats. World J Gastroenterol (2014) 0.81
Selective COX-2 inhibition reduces leukocyte sticking and improves the microcirculation in TNBS colitis. Dig Dis Sci (2006) 0.81
Recovery of ischaemic injured porcine ileum: evidence for a contributory role of COX-1 and COX-2. Gut (2002) 0.81
Effects of Rhizophora mangle on Experimental Colitis Induced by TNBS in Rats. Evid Based Complement Alternat Med (2012) 0.81
Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection. Bioorg Med Chem (2013) 0.81
Effect of COX-2 inhibitor lumiracoxib and the TNF-α antagonist etanercept on TNBS-induced colitis in Wistar rats. J Mol Histol (2012) 0.80
Effect of COX-2 inhibitor after TNBS-induced colitis in Wistar rats. J Mol Histol (2009) 0.80
Enterococcus faecalis Gelatinase Mediates Intestinal Permeability via Protease-Activated Receptor 2. Infect Immun (2015) 0.79
Wood smoke enhances cigarette smoke-induced inflammation by inducing the aryl hydrocarbon receptor repressor in airway epithelial cells. Am J Respir Cell Mol Biol (2015) 0.79
The role of selective cyclooxygenase isoforms in human intestinal smooth muscle cell stimulated prostanoid formation and proliferation. Mediators Inflamm (1998) 0.78
Glutamate microinjection into the hypothalamic paraventricular nucleus attenuates ulcerative colitis in rats. Acta Pharmacol Sin (2013) 0.78
Commonality of defensive roles of COX-2 in the lung and gut. Am J Pathol (2006) 0.77
Differential regulation of prostaglandin E biosynthesis by interferon-gamma in colonic epithelial cells. Br J Pharmacol (2004) 0.76
Effects of N-acetylcysteine plus mesalamine on prostaglandin synthesis and nitric oxide generation in TNBS-induced colitis in rats. Dig Dis Sci (2008) 0.76
Activation of the prostaglandin D2 metabolic pathway in Crohn's disease: involvement of the enteric nervous system. BMC Gastroenterol (2015) 0.76
Crystallization of interleukin-18 for structure-based inhibitor design. Acta Crystallogr F Struct Biol Commun (2015) 0.75
Are cyclooxygenase 2 inhibitors free of gastrointestinal side effects? West J Med (2001) 0.75
Regulated spatial distribution of cyclooxygenases and lipoxygenases in Crohn's ulcer. Mediators Inflamm (2006) 0.75
Harnessing the natural inhibitory domain to control TNFα Converting Enzyme (TACE) activity in vivo. Sci Rep (2016) 0.75
MDR1A deficiency restrains tumor growth in murine colitis-associated carcinogenesis. PLoS One (2017) 0.75
Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. Pharmacol Ther (2017) 0.75
Decreased total antioxidant capacity in plasma, but not tissue, in experimental colitis. Dig Dis Sci (2008) 0.75
Effects of lipopolysaccharide on gastric stasis: role of cyclooxygenase. Dig Dis Sci (2006) 0.75
Low endogenous prostaglandin E2 predisposes to relapsing inflammation in experimental rat enterocolitis. Dig Dis Sci (2000) 0.75
Gastritis induced by Helicobacter pylori infection in experimental rats. Dig Dis Sci (2010) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology (1989) 7.59
Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A (1991) 5.07
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82
Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res (1995) 4.52
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 4.39
Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A (1994) 4.21
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A (1994) 4.15
Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem (1993) 4.05
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A (1992) 3.65
Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature (1972) 3.30
Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci U S A (1994) 3.20
Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 2.98
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res (1995) 2.74
A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology (1995) 2.30
Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci U S A (1983) 2.06
Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med (1987) 2.02
Treatment with 16,16'-dimethyl prostaglandin E2 before and after induction of colitis with trinitrobenzenesulfonic acid in rats decreases inflammation. Gastroenterology (1989) 1.95
Regulation of macrophage tumor necrosis factor production by prostaglandin E2. Biochem Biophys Res Commun (1986) 1.95
Monitoring mRNA expression by polymerase chain reaction: the "primer-dropping" method. Anal Biochem (1994) 1.93
Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology (1996) 1.81
An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol (1990) 1.71
Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med (1991) 1.67
Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys (1993) 1.59
Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest (1995) 1.55
Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci U S A (1991) 1.47
Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther (1995) 1.37
A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol (1994) 1.28
Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology (1992) 1.23
Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology (1990) 1.17
Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem (1996) 1.15
Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA. Biochem Biophys Res Commun (1993) 1.12
Expression of cyclooxygenase types 1 and 2 in human fetal membranes at term. Am J Obstet Gynecol (1995) 1.08
Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut (1996) 1.06
An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm (1990) 1.06
Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology (1992) 1.06
Inhibition of the n-formylmethionyl-leucyl-phenylalanine induced respiratory burst in human neutrophils by adrenergic agonists and prostaglandins of the E series. Can J Physiol Pharmacol (1981) 1.05
Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol (1995) 0.96
Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers. Dig Dis Sci (1991) 0.95
Induction of cyclooxygenase type-2 (COX-2) in rat endometrium at the peak of serum estradiol during the estrus cycle. Jpn J Pharmacol (1995) 0.82
An overview of the long-term safety experience of nabumetone. Drugs (1990) 0.80
Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac. Dig Dis Sci (1994) 0.79
Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology (1989) 7.59
The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol (1999) 7.19
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med (2000) 3.71
Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway. Nat Med (2001) 3.17
Sucrose: a novel permeability marker for gastroduodenal disease. Gastroenterology (1993) 2.46
Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology (1998) 2.46
A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology (1995) 2.30
Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci (2001) 2.06
Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology (2001) 2.03
Recurrent aphthous ulcers today: a review of the growing knowledge. Int J Oral Maxillofac Surg (2004) 1.89
Modulation of host response to Escherichia coli o157:H7 infection by anti-CD18 antibody in rabbits. Gastroenterology (1994) 1.85
Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci U S A (2001) 1.84
Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol (1999) 1.83
Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J (1997) 1.80
Suppression of fever at near term is associated with reduced COX-2 protein expression in rat hypothalamus. Am J Physiol Regul Integr Comp Physiol (2002) 1.80
Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature (1986) 1.73
Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology (1997) 1.69
Proteinase-activated receptor 2 (PAR2)-activating peptides: identification of a receptor distinct from PAR2 that regulates intestinal transport. Proc Natl Acad Sci U S A (1998) 1.61
Representation of three-dimensional objects by the rat perirhinal cortex. Hippocampus (2012) 1.60
Indiscriminate loss of myenteric neurones in the TNBS-inflamed guinea-pig distal colon. Neurogastroenterol Motil (2005) 1.51
Apoptosis induced by inhibition of intercellular contact. J Cell Biol (1994) 1.49
Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am J Physiol (1990) 1.46
Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol (2007) 1.45
Nitric oxide synthesis inhibition increases epithelial permeability via mast cells. Am J Physiol (1994) 1.44
Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A (2001) 1.39
Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol (1995) 1.36
Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice. Gut (1999) 1.35
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol (2010) 1.32
The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol (2001) 1.32
Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol (1995) 1.31
Sensory substance P innervation of the stomach and pancreas. Demonstration of capsaicin-sensitive sensory neurons in the rat by combined immunohistochemistry and retrograde tracing. Gastroenterology (1984) 1.29
Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol (2007) 1.29
Nitric Oxide. V. therapeutic potential of nitric oxide donors and inhibitors. Am J Physiol (1999) 1.27
Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Actions (1988) 1.27
NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther (1997) 1.26
Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am J Physiol Gastrointest Liver Physiol (2000) 1.25
Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists. Gastroenterology (1987) 1.24
Plasticity of the enteric nervous system during intestinal inflammation. Neurogastroenterol Motil (2005) 1.23
Persistent epithelial dysfunction and bacterial translocation after resolution of intestinal inflammation. Am J Physiol Gastrointest Liver Physiol (2001) 1.23
Changes in colonic motility and the electrophysiological properties of myenteric neurons persist following recovery from trinitrobenzene sulfonic acid colitis in the guinea pig. Neurogastroenterol Motil (2007) 1.23
Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology (1999) 1.22
The MBEC Assay System: multiple equivalent biofilms for antibiotic and biocide susceptibility testing. Methods Enzymol (2001) 1.22
Plasticity of enteric nerve functions in the inflamed and postinflamed gut. Neurogastroenterol Motil (2009) 1.21
Prolonged colonic epithelial hyporesponsiveness after colitis: role of inducible nitric oxide synthase. Am J Physiol (1999) 1.21
A simple, non-invasive marker of gastric damage: sucrose permeability. Lancet (1994) 1.20
Effects of chemical sympathectomy and sensory nerve ablation on experimental colitis in the rat. Am J Physiol (1997) 1.19
Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci (1989) 1.19
The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br J Pharmacol (1988) 1.18
Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br J Pharmacol (2001) 1.18
Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis. Neurogastroenterol Motil (2005) 1.17
Enteric glia. Neurogastroenterol Motil (2004) 1.16
Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol (1994) 1.16
Role of mucus in the repair of gastric epithelial damage in the rat. Inhibition of epithelial recovery by mucolytic agents. Gastroenterology (1986) 1.16
The effect of enterohemorrhagic Escherichia coli O157:H7 on intestinal structure and solute transport in rabbits. Gastroenterology (1993) 1.15
Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. J Allergy Clin Immunol (2000) 1.15
Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther (2005) 1.15
NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br J Pharmacol (2000) 1.14
Role of prostanoids in the protective actions of BW755C on the gastric mucosa. Eur J Pharmacol (1985) 1.14
Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol (1996) 1.14
The participation of the sympathetic innervation of the gastrointestinal tract in disease states. Neurogastroenterol Motil (2009) 1.13
Lipopolysaccharide induced acute red eye and corneal ulcers. Exp Eye Res (1997) 1.12
Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci (1998) 1.11
Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1). Br J Pharmacol (1999) 1.11
Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc Natl Acad Sci U S A (2000) 1.11
Distribution of nitric oxide synthase in rat dorsal vagal complex and effects of microinjection of nitric oxide compounds upon gastric motor function. J Comp Neurol (1997) 1.11
Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants. Prostaglandins (1986) 1.10
Prevention of endotoxin-induced gastrointestinal damage by CV-3988, an antagonist of platelet-activating factor. Eur J Pharmacol (1986) 1.10
Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol (2000) 1.09
An electrophysiological and anatomical study of intestinal afferent fibres in the rat. J Physiol (1988) 1.09
Role of oxygen-derived free radicals in indomethacin-induced gastric injury. Am J Physiol (1991) 1.09
Antineuronal antibodies in idiopathic achalasia and gastro-oesophageal reflux disease. Gut (2003) 1.08
Modulation of ion channels in rod photoreceptors by nitric oxide. Neuron (1994) 1.08
Spontaneously developing chronic colitis in IL-10/iNOS double-deficient mice. Am J Physiol Gastrointest Liver Physiol (2000) 1.07
Immunologic, functional, and morphological characterization of three new human small intestinal epithelial cell lines. Gastroenterology (1996) 1.07
Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. Am J Physiol Gastrointest Liver Physiol (2000) 1.06
Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther (1997) 1.06
Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut (2003) 1.06
Induction of cyclooxygenase 1 and 2 in the rat stomach during endotoxemia: role in resistance to damage. Gastroenterology (1997) 1.06
Temporal distribution of neuronal and inducible nitric oxide synthase and nitrotyrosine during colitis in rats. Neurogastroenterol Motil (1999) 1.06
The roles of ethanol and of acid in the production of gastric mucosal erosions in rats. Virchows Arch B Cell Pathol Incl Mol Pathol (1981) 1.05
Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Neurogastroenterol Motil (2009) 1.05
Correlation of morphology, electrophysiology and chemistry of neurons in the myenteric plexus of the guinea-pig distal colon. J Auton Nerv Syst (1999) 1.05
Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. Br J Pharmacol (2001) 1.05
Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis. Hepatology (2000) 1.05
Distribution of calcitonin gene-related peptide, somatostatin, substance P and vasoactive intestinal polypeptide in experimental colitis in rats. Neurogastroenterol Motil (1998) 1.05
Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci (1998) 1.05
Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. Br J Pharmacol (2000) 1.03